Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04439-x In a whole-exome sequencing analysis, the beneficial effects of the SGLT2 inhibitor dapagliflozin in reducing the risk of future heart failure hospitalization in individuals with type 2 diabetes were markedly greater in individuals who carried a cardiomyopathy-associated genetic variant compared with noncarriers, suggesting a personalized preventative therapy based on genetic information.
Nature Medicine, Published online: 08 June 2026;
doi:10.1038/s41591-026-04439-x
In a whole-exome sequencing analysis, the beneficial effects of the SGLT2 inhibitor dapagliflozin in reducing the risk of future heart failure hospitalization in individuals with type 2 diabetes were markedly greater in individuals who carried a cardiomyopathy-associated genetic variant compared with noncarriers, suggesting a personalized preventative therapy based on genetic information.
— Source: Nature Medicine (https://www.nature.com/articles/s41591-026-04439-x)